DSC
HUMA icon

Duncker Streett & Co’s Humacyte HUMA Stock Holding History

Duncker Streett & Co’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-800
Closed -$4.04K – 521
2024
Q4 		$4.04K Buy
+800
New +$3.96K ﹤0.01% 479

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Duncker Streett & Co's HUMA Position: Q1 2025 in Review

Duncker Streett & Co sold out of Humacyte (HUMA) in Q1 2025, closing a stake of 800 shares — an estimated $4.04K sold.

Duncker Streett & Co first reported a position in HUMA in Q4 2024 and held it in 1 quarter. The position peaked at $4.04K in Q4 2024. 168 funds tracked by Wall St. Rank hold HUMA as of Q1 2025.

  • Duncker Streett & Co reported no remaining Humacyte position as of Q1 2025 after selling out during the quarter.
  • Duncker Streett & Co sold 800 Humacyte shares in Q1 2025, an estimated $4.04K.
  • Duncker Streett & Co first reported a position in Humacyte in Q4 2024 and held it in 1 quarter.
  • Duncker Streett & Co's Humacyte position peaked at $4.04K in Q4 2024.
  • 168 funds tracked by Wall St. Rank held Humacyte as of Q1 2025.

Based on Duncker Streett & Co's 13F filing for Q1 2025, filed 22 Apr 2025.